Eli Lilly & Co. (LLY)

113.17
0.37 0.33
NYSE : Health Technology
Prev Close 112.80
Open 112.77
Day Low/High 112.45 / 114.04
52 Wk Low/High 101.36 / 132.13
Volume 2.27M
Avg Volume 3.27M
Exchange NYSE
Shares Outstanding 960.13M
Market Cap 109.00B
EPS 3.10
P/E Ratio 25.23
Div & Yield 2.58 (2.21%)
Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

The Gold Rush of 2019

The Gold Rush of 2019

Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft is to be bought for about $2 billion by DXC Technology.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

The company expects revenue to jump 12% year over year.

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.

Bigfoot Biomedical Announces Next Step For Connected Insulin Injection System

Bigfoot Biomedical Announces Next Step For Connected Insulin Injection System

Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support...

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Jim Cramer: They Might Be Done

Jim Cramer: They Might Be Done

Whether this is the end of the slump is still up for debate, but the crash since October has been brutal and all bear markets end the same way.

Eli Lilly's Technical Setup Looks So-So, So Be Ready to Take Action

Eli Lilly's Technical Setup Looks So-So, So Be Ready to Take Action

A close below $105 for the drugmaker's shares would be bearish based on its charts.

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Buying stocks now means you are in the uncomfortable position of fighting the Fed as it tries to slow the economy.

Stocks Hit New Lows After Early Rally as Fed Hikes Key Rate

Stocks Hit New Lows After Early Rally as Fed Hikes Key Rate

Stocks plunged Wednesday afternoon following the Federal Reserve's decision to raise rates by a quarter point.

Eli Lilly Shares Jump After Dividend Boost, Robust 2019 Outlook

Eli Lilly Shares Jump After Dividend Boost, Robust 2019 Outlook

Eli Lilly jumps Wednesday after it boosts its quarterly dividend and issues stronger-than-expected 2019 profits forecasts thanks to stronger demand for new medicines and its existing diabetes drug franchise.

I Have No Idea What It Would Take to Rally This Market

We know we’re at the point where selling begets selling.

AC Immune And Lilly Announce License And Collaboration Agreement

AC Immune And Lilly Announce License And Collaboration Agreement

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of...

This Healthcare Name Has Broken Out of a Box; New Highs to Come

Lilly’s breakout has the stock poised to move through the $120 area.

3 Tips for Trading the Fed's More Dovish Stance

3 Tips for Trading the Fed's More Dovish Stance

Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AES, ALIM, APPS, EXAS, INVH, LBRDA, LBRDK, LLY, TLK Downgrades: CTT, DRH, HA, MTDR, ORIT, RNG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly Shares Decline on Tuesday Despite Strong Earnings Release

Eli Lilly's excellent earnings weren't excellent enough.

TheStreet Quant Rating: B- (Buy)